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Background: Studies have shown that red cell distribution width (RDW) is related to outcome in chronic
heart failure (CHF). The pathophysiological process is unknown. We studied the relationship between
RDW and erythropoietin (EPO) resistance, and related factors such as erythropoietic activity, functional
iron availability and hepcidin.
Methods and Results: In the Mechanisms of Erythropoietin Action in the Cardiorenal Syndrome (EPO-
CARES) study, which investigates the role of EPO in 54 iron-supplemented anemic patients with CHF and
chronic kidney disease (CKD) (n 5 35 treated with 50 IU/kg/wk Epopoetin beta, n 5 19 control), RDW
was not associated with EPO resistance. We defined EPO resistance by EPO levels (r5 0.12, P5 .42), the
observed/predicted log EPO ratio (r 5 0.12, P 5 .42), the increase in reticulocytes after 2 weeks of EPO
treatment (r 5 0.18, P 5 .31), and the increase of hemoglobin after 6 months of EPO treatment (r 5
0.26, P 5 .35). However, RDW was negatively correlated with functional iron availability (reticulocyte
hemoglobin content, r5 0.48, P! .001, and transferrin saturation, r5 0.39, P5 .005) and positively
with erythropoietic activity (soluble transferrin receptor, r 5 0.48, P! .001, immature reticulocyte frac-
tion, r 5 0.36, P 5 .01) and positively with interleukin-6 (r 5 0.48, P ! .001). No correlation existed
between hepcidin-25 and RDW.
Conclusions: EPO resistance was not associated with RDW. RDW was associated with functional iron
availability, erythropoietic activity, and interleukin-6 in anemic patients with CHF and CKD. (J Cardiac
Fail 2011;17:626e633)
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association between RDWand the risk of adverse outcomes
in patients with chronic and acute heart failure,1e4 in
patients with stable coronary artery disease,5 and even in
a community-based cohort.6e8 The pathophysiological
mechanism responsible for the association between RDW
and adverse outcomes, is open to question. Anemia is
highly prevalent in chronic heart failure (CHF) and is asso-
ciated with morbidity and mortality.9 Most factors that
cause anemia through ineffective red cell production or
increased red cell destruction could cause anisocytosis.
Importantly, however, RDW remained an independent pre-
dictor of outcome after adjusting for hemoglobin level.1
Erythropoietin (EPO) resistance, that is the inadequate
bone marrow response to endogenous and/or exogenous
EPO leading to an impaired red blood cell line, plays an im-
portant role in anemia of CHF and chronic kidney disease
(CKD).10 Resistance to EPO is associated with morbidity
and mortality.11 Several authors hypothesize that EPO
resistance could explain the association between RDW
and outcome.2,4,12 Inflammation and disordered iron metab-
olism are factors that can cause EPO resistance and indeed,
recent studies have shown that inflammatory markers, EPO
levels, and decreased functional iron availability correlate
with RDW.2,4 However, no direct data are available as to
the association between RDW and EPO resistance. The
Mechanisms of Erythropoietin Action in the Cardiorenal
Syndrome (EPOCARES) study created an opportunity to
investigate the association between RDW and EPO resis-
tance in iron-supplemented, EPO-naive patients with CHF
and CKD.11 Because a universally accepted definition of
EPO resistance does not exist, we estimated EPO resistance
in three ways using the log observed/predicted ratio (O/P),
which reflects the EPO level for the degree of anemia13; the
extent in increase of reticulocyte count, soluble transferrin
receptor or immature reticulocyte fraction after 2 weeks
of exogenous EPO treatment; and the hemoglobin increase
after 6 months of EPO treatment. In addition, we investi-
gated the role of associated factors, such as inflammation,
erythropoietic activity (rate of red cell production), func-
tional iron availability, and hepcidin.
Methods
Study Design and Patients
The study design of the EPOCARES study (ClinicalTrials.gov
number NCT 00356733) has been published elsewhere.14 In short,
the EPOCARES study is an open-label, prospective, randomized
trial, in which patients with CHF, CKD (glomerular filtration rate
by Cockroft-Gault equation of 20 to 70 mL/min) and mild anemia
(hemoglobin 10.3 to 12.6 g/dL for men and 10.3 to 11.9 g/dL for
women) are included to test the hematopoietic and nonhemato-
poietic responses to EPO treatment. Exclusion criteria, among
others, were erythropoietic therapy within 6 months, bleeding,
hemolysis, hemoglobinopathies, chronic inflammatory disease, or
malignancy. Hemoglobin (Hb) level for inclusion was measured af-
ter at least 4 weeks of oral iron supplementation, if tolerated.
The diagnostic criteria for CHF were those recommended by the
European Society of Cardiology guidelines.15 Patients with heartfailure with reduced left ventricular ejection fraction (HFREF) as
well as patients with preserved left ventricular ejection fraction
(HFPEF) were included.16 The Medical-Ethical Committee ap-
proved the protocol of the study and informed consent was obtained
from all subjects. Procedures were in accordance with the Helsinki
Declaration and all patients gave written consent.
Patients were randomized on a 1:1:1 basis, after they had been
clinically stable on maximal tolerated doses of a ß-blocker, an
angiotensin-converting enzyme inhibitor or an angiotensin recep-
tor blocker for at least 4 weeks. One group received 50 IU$kg$wk
Epopoetin beta (Neorecormon, Roche Pharmaceuticals) and their
Hb was kept at baseline level by phlebotomies during the first
6 months. One group received 50 IU/kg/wk Epopoetin beta and
their Hb could rise (to a certain safety level). The third group
received standard treatment. Most biochemical measurements
were performed at baseline, after 2 weeks and monthly thereafter.
Blood samples were drawn between 8 and 9 AM in supine position
and stored at 80C until analysis.
Biomarker Analysis
Levels of Hb, hematocrit, MCV, RDW, white blood cells,
platelets, reticulocyte count and reticulocyte hemoglobin content
(RET-He) were measured with the use of a Sysmex XE-2100
hematology analyzer (Toa Medical, Kobe, Japan).
High sensitivity C-reactive protein (hs-CRP) was determined
by particle-enhanced immunonephelometry using a standard
Cardio-Phase hs-CRP for BNII (Dade Behring Holding GmbH,
Liederbach, Germany). Plasma interleukin-6 (IL-6) levels (pg/mL)
were measured in duplo using a commercially available high sensi-
tive ELISA kit (R&D Systems, Minneapolis, MN).
As a marker of total iron stores,17 ferritin was determined using
a sandwich immunoassay on an Acces2 immunoanalyzer within
a Dx automated system from Beckman Coulter (Brea, CA). Func-
tional iron availability was determined by measuring transferrin
saturation (TSAT), soluble transferrin receptor (sTfR) and RET-
He. TSAT was calculated from serum iron and transferrin esti-
mates obtained with standard methods on a Beckman Coulter
Dx. sTfR assay was performed with an immunoassay on a BNPro-
Spec nephelometer from Siemens (Marburg, Germany). RET-He
was performed using flow cytometric analysis with Ret-Search
(II) dye on a Sysmex XE-2100 hematology analyzer (Toa Med-
ical, Kobe, Japan).
Erythropoietin Levels, Erythropoietic Activity, and EPO
Resistance
Serum EPO levels were measured by a 2-site sandwich chem-
iluminescent immunoassay on an IMMULITE 2000 platform
(Siemens Healthcare Diagnostics, Breda, the Netherlands). As
markers of erythropoietic activity, we measured sTfR and assessed
the ratio of young immature reticulocytes (IRF). Reticulocytes have
variable amounts of RNA, which correlates with their maturation.
The fluorescent intensity of a reticulocyte,measured by using a fluo-
rescent polymethine dye, is proportional to the quantity of RNA.
Reticulocytes are thus divided in the most immature, moderately
immature (together comprising IRF), and mature reticulocytes.
An increase in IRF precedes the increase in reticulocyte count
and is therefore used as a marker of erythropoietic activity.18,19
EPO resistance was measured in multiple ways. Endogenous
EPO resistance was determined by defining the EPO levels for
the degree of anemia, by calculating the observed/predicted log
(EPO) ratio (O/P ratio). EPO levels were defined as inappropriate
628 Journal of Cardiac Failure Vol. 17 No. 8 August 2011at an O/P ratio!0.80. The O/P ratio can be calculated as follows:
O/P ratio 5 (log(observed Epo))/(log(predicted Epo)]. To predict
EPO levels, we used the regression equation as defined by Opasich
et al: log(Epo) 5 4.746e(0.275  Hb).13 Patients were stratified
by O/P ratio at inclusion. Exogenous EPO response was measured
as the increase of reticulocyte count, sTfr, and IRF after 2 weeks
of EPO treatment and by assessing the Hb response after 6 months
of EPO treatment.
Hepcidin-25
Serum hepcidin-25 measurements were performed by a combi-
nation of weak cation exchange chromatography and time-
of-flight mass spectrometry.20 Serum hepcidin-25 concentrations
were expressed as nmol/l. The lower limit of detection of this
method was 0.5 nM; average coefficients of variation were 2.7%
(intra-run) and 6.5% (inter-run). The median reference level of
serum hepcidin-25 as measured at 8:30 AM is 2.9 nM, range
0.5 to 8.2 nM.21,22
Statistical Analysis
Data are presented as medians with inter-quartile ranges for
non-normally distributed variables and means 6 standard devia-
tion (SD) for normally distributed continuous variables. Unpaired
data were compared with the unpaired t-test or the Mann-Whitney
U test. For paired data we used the paired t-test or Wilcoxon rank
test. Pearson correlation coefficient was used to test univariate cor-
relation with RDW in normally distributed variables. Skewed vari-
ables were log-transformed. Analysis of variance was applied on
parametric variables. Differences were considered significant
when P ! .05. Following univariate correlations, variables with
a P value!.05, were entered into a multivariable linear regression
model with stepwise forward selection process, to identify
independent predictors of RDW. For statistical analyses the Statis-




The original study population of the EPOCARES study
comprising 62 patients. Five patients withdrew their
informed consent and 1 patient was excluded because of
malignancy (diagnosed on routine X-ray). Baseline RDW
data were missing for 2 patients. Baseline characteristics
of the 54 patients for this study are presented in Table 1,
divided according to tertiles of RDW. Univariate linear cor-
relations are listed in Table 2. In Table 3, the multivariable
regression analysis is shown.
All patients had CKD, CHF, and anemia, as shown by the
decreased estimated glomeral filtration rate (eGFR), using
the modified diet in renal disease formula, higher NT-
proBNP the lower LVEF, and the lower Hb levels. Vitamin
B12 and folate levels were normal and hemolysis was ab-
sent, as measured by lactodehydrogenase levels. CRP and
hs-CRP levels were only slightly elevated, showing that
the study involved chronic stable patients without evident
inflammation. At baseline there was no significant differ-
ence in all previously mentioned variables among the 3
study groups.RDW at Baseline
The median RDW value at baseline was 14.0% (inter-
quartile range 13.3-15.1), and 26% of the patients had
a level above the upper limit (O15%), which corresponds
with data from other studies.1e5,23 In our normocytic ane-
mic population, a higher RDW was not associated with
baseline Hb levels, hematocrit or MCV. RDW showed no
correlation with renal function, as measured by creatinine,
Cockroft-Gault equation, modified diet in renal disease for-
mula, or cystatin C, nor with cardiac function as measured
by left ventricular ejection fraction or NTproBNP levels at
baseline (Tables 1 and 2).
Iron Metabolism
In these patients on oral iron supplementation (if tolerated)
without overt inflammation, ferritin at baseline was !100
ng/mL in 22 of the patients (41%), indicating that some pa-
tients may have been (relatively) iron deficient despite oral
supplementation. Indeed, also baseline TSAT levels were
low in some patients (!20% in 26 of the patients or !
15% in 8 patients). However, in the 35 patients that received
EPO, there was no significant decrease in RET-He after 2
weeks of EPO treatment (P 5 .32). This indicates that there
was no iron-restricted erythropoiesis in these patients. There-
fore no direct evidence of decreased functional iron availabil-
ity in the patients that received EPO was observed.24 At
baseline there was no difference in the variables for iron me-
tabolism between the EPO-treated groups versus the control
group, thereforewe conclude that therewas no iron-restricted
erythropoiesis in thewhole study population. Total iron store
variables at baseline did not correlate with RDW (Tables 1
and 2). However, functional iron availability was negatively
associated with RDW; patients in the highest RDW-tertile
had both significant lower TSAT level and RET-He levels
at baseline, as demonstrated by univariate correlation in
Table 2 and further depicted in Figure 1A. Baseline
hepcidin-25 showed no significant correlation with RDW.
Inflammation
A positive correlation was observed between RDW and
IL-6 at baseline, but this was not the case with CRP, nor
with hs-CRP. There was a negative correlation between
IL-6 with RET-He (respectively, P 5 .03, r 5 0.30).
As previously described, there was no correlation between
both IL-6 and hs-CRP with hepcidine-25 (respectively,
P 5 .93, r 5 0.12 and P 5 .27, r 5 0.20) in our
population.25
EPO Levels, Erythropoietic Activity, and EPO
Resistance
There was a positive correlation between RDW and
erythropoietic activity as measured by sTfr and IRF at base-
line (univariate correlation Table 2 and scatterplot in
Fig. 1B and 1C), but this was apparently not related to









RDW $ 14.8 % P Value
Age (y) 74 (69-80) 72 (68-75) 77 (71-82) 77 (66-81) .27
Male sex, n (%) 35 (65%) 12 (67%) 12 (67%) 11 (61.1%) .49
Hemoglobin (g/dL) 11.8 6 0.9 11.6 6 0.9 12.1 6 0.9 11.8 6 0.9 .36
Hematocrit (%) 0.35 6 0.03 0.35 6 0.03 0.32 6 0.12 0.34 6 0.09 .71
MCV (/mm3) 90.0 6 4 90 6 3 91 6 5 89 6 4 .60
MDRD (mL$min$1.73 m2) 34.7 6 13.8 30.5 6 13.8 39.0 6 15.3 34.7 6 11.5 .18
Cockroft Gault (mL/min) 36.7 6 14.9 33.9 6 11.6 38.4 6 17.2 37.8 6 15.7 .62
Cystatin C (mg/L) 1.72 (1.36-2.47) 2.03 (1.50-2.72) 1.49 (1.08-2.45) 1.76 (1.48-2.37) .43
NTproBNP (pg/mL) 1453 (718-2655) 1128 (482-1887) 1306 (718-2162) 2352 (926-6688) .08
LVEF (%) 43.8 6 11.7 45.7 6 11.8 47.1 6 10.3 37.9 6 10.5 .97
Iron (mmol/L) 10 (8.8-14.0) 12 (10-14) 10 (9-15) 9 (8-12) .08
Ferritin (ng/mL) 126 (75-175) 140 (68-198) 126 (90-195) 106 (55-141) .46
Transferrin (g/L) 2.2 (2.0-2.5) 2.1 6 0.23 2.3 6 0.32 2.4 6 0.51 .19
Transferrin saturation (%) 20 (15.8-25.0) 24 (18.8-29.0) 20 (16.5-25.3) 17 (14.0-20.3) .020
Ret-He (fmol) 1.9 6 0.14 1.94 6 0.09 1.93 6 0.14 1.80 6 0.14 .003
Hepcidin-25 (nM) 5.9 (3.6-7.9) 6.9 (3.5-10.0) 5.8 (4.3-7.4) 5.0 (2.9-8.5) .64
Soluble transferrin receptor (mg/L) 1.40 6 0.47 1.19 6 0.31 1.35 6 0.42 1.67 6 0.53 .003
Erythropoietin (IU/L) 13.0 (7.0-16.0) 11.5 (6.8-15.3) 14.5 (10.0-18.0) 12.5 (7.0-16.8) .59
O/P ratio 0.78 6 0.19 0.74 6 0.18 0.80 6 0.19 0.80 6 0.20 .55
Reticulocyte count (1012/L) 0.046 6 0.015 0.038 6 0.01 0.050 6 0.01 0.049 6 0.02 .026
IRF (%) 8.8 (5.4-11.4) 5.6 (3.8-9.2) 9.2 (6.4-11.2) 11.0 (7.4-14.7) .003
CRP (mg/L) 6 (2-12) 2.5 (1.0-5.3) 7.0 (2.0-12.0) 7.0 (3.8-20) .03
hs-CRP (mg/L) (n 5 37) 5.8 (2.04-10.4) 2.4 (0.9-6.4) 6.2 (2.2-10.2) 7.2 (3.8-20.2) .09
IL-6 (pg/mL) 3.66 (1.90-5.57) 2.5 (1.6-3.3) 3.66 (1.8-4.8) 7.1 (3.6-10.7) !.001
Vitamin B12 (pg/mL) 277 (214-408) 277 (232-468) 239 (171-362) 329 (259-515) .16
Folate (ng/mL) 17.5 (12.5-40.7) 20.2 (11.6-45.0) 16.5 (11.2-29.7) 21.7 (15.4-45.0) .48
Lactate dehydrogenase (U/L) 408 (353-487) 397 (326-428) 422 (370-574) 411 (373-534) .19
Albumin (g/L) 36.7 6 3.0 37.0 6 2.3 37.8 6 2.3 35.4 6 3.6 .045
Total cholesterol (mmol/L) 4.1 6 1.1 4.6 6 1.26 4.1 6 0.98 3.6 6 0.94 .044
MCV 5 mean corpuscular volume; NTproBNP 5 N-terminal pro-brain natriuretic peptide; LVEF 5 left ventricular ejection fraction; Ret-He 5 reticu-
locyte hemoglobin content; O/P ratio 5 log observed/predicted erythropoietin ratio; IRF 5 immature reticulocyte fraction; CRP 5 C-reactive protein; hs-
CRP 5 high sensitivity CRP; IL-6 5 interleukin-6; MDRD 5 estimated glomerular filtration rate by modified diet in renal disease formula.
*Values in mean 6 standard deviation or median (interquartile range).
RDW and EPO Resistance  Emans et al 629higher endogenous EPO levels, because there was no corre-
lation between baseline EPO levels and RDW (Table 2).
The EPO level was defined for the degree of anemia by
the baseline O/P ratio. Given that the average O/P ratio was
only slightly below 0.80, the endogenous EPO production
was partly preserved in this population with CKD and
CHF. We found no correlation with RDW and endogenous
EPO resistance as measured by the O/P ratio (Table 2).
Of the 54 patients, 35 patients received EPO treatment.
After 2 weeks of EPO treatment, the reticulocyte count
significantly increased (P ! .0001), as did sTfR (P !
.0001) and IRF (P5 .027). Also, after 2 weeks of EPO treat-
ment, RDW was significantly increased (P ! .001). In the
control group, without EPO treatment, the reticulocyte count
(P 5 .21) did not change, nor did IRF (P 5 .62) or RDW
(P 5 .80).
The magnitude of increase in reticulocyte count in the
EPO treated group, however, did not correlate with the
baseline RDW values. Neither did the extent in increase
of sTfR and IRF after 2 weeks EPO treatment correlate
with baseline RDW. These correlations between the
increase in reticulocyte count, sTfR, and IRF after 2 weeks
with log-transformed RDW at baseline are depicted in
Figure 2A, 2B, and 2C.
In 17 of the 35 patients who received EPO treatment, the
Hb was left to increase. After 6 months of EPO treatment,the Hb in these patients was significantly increased com-
pared to baseline Hb (P5 .001). The magnitude in increase
of Hb after 6 months, showed no correlation with RDW at
baseline (P 5 .35, r 5 0.26). Neither was there any corre-
lation with baseline RDW and the magnitude of increase in
reticulocyte count, sTfR, and IRF after 6 months of EPO
treatment (resp. P 5 .54, P 5 .39, and P 5 .36). These
results show that there is neither a correlation between
baseline RDW and response to exogenous EPO.
Multivariable Regression Model
After entering all baseline biomarkers with a significant
univariate correlation with baseline RDW in a multivariable
regression model, on a stepwise forward selection, sTfR,
IL-6, RET-He, and IRF proved to be independent predictors
of RDW (Table 3).Discussion
A strong independent association exists between RDW,
a measure of anisocytosis, and adverse outcomes in cardio-
vascular disease (eg, CHF). The underlying process that
links RDW to outcome is unknown. One of the main find-
ings of this study is that EPO resistance as measured by
several different methods was not associated with RDW.
Table 2. Univariate Correlation Coefficients of Clinical and










Cockroft Gault 0.11 .43
Cystatin C 0.26 .85
NTproBNP 0.24 .10
LVEF 0.17 .22
Serum iron 0.33 .02
Ferritin 0.21 .16
Transferrin 0.34 .012
Transferrin saturation 0.39 .005
Ret-He 0.48 !.001
Hepcidin 0.25 .07
Soluble transferrin receptor 0.48 !.001
Erythropoietin 0.12 .42
O/P ratio 0.11 .42
Reticulocyte count 0.13 .36
IRF 0.36 .01
CRP 0.23 .11
hs-CRP (n 5 37) 0.27 .13
IL-6 0.48 !.001
Vitamin B12 0.25 .073
Folate 0.07 .61
Lactate dehydrogenase 0.21 .13
Albumin 0.17 .23
Total cholesterol 0.27 .055
MCV 5 mean corpuscular volume; NTproBNP 5 N-terminal pro-brain
natriuretic peptide; LVEF 5 left ventricular ejection fraction; Ret-He 5
reticulocyte hemoglobin content; O/P ratio 5 log observed/predicted
erythropoietin ratio; IRF 5 immature reticulocyte fraction; CRP 5 C-re-
active protein; hs-CRP 5 high sensitivity CRP; IL-6 5 interleukin-6;
MDRD5 estimated glomerular filtration rate by modified diet in renal dis-
ease formula.
All nonparametric variables were considered for analysis after logarith-
mic transformation.
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RDW was associated with functional iron availability and
erythropoietic activity. After multivariate analysis, markers
of functional iron availability, erythropoietic activity, and
IL-6 were independent predictors of RDW. However, hepci-
din levels were not significantly associated with RDW. This
underscores earlier findings that, in low-inflammatory pa-
tient groups, hepcidin levels are not associated with
markers of inflammation.25,26Table 3. Stepwise Multivariate Linear Regression for RDW









Soluble transferrin receptor 1 0.218 0.483 !.001
Interleukin-6 2 0.356 0.394 !.001
Reticulocyte hemoglobin
content
3 0.434 0.309 !.001
Immature reticulocyte fraction 4 0.529 0.278 !.001
*All non-parametric variables were considered for analysis after loga-
rithmic transformation.EPO resistance, defined as an inadequate bone marrow
response to exogenous or endogenous EPO, contributes to
anemia11 and is associated with increased mortality in
patients with heart and/or kidney failure.27,28 Indeed, EPO
levels in patients with CKD and/or CHF are higher as com-
pared to healthy controls, but inappropriately low for the
degree of anemia.10,13 This observation indicates a relative
EPO deficiency as well as a reduced bone marrow response
to endogenous EPO.11 Approximately, 10% of CKD patients
treated with exogenous EPO have an inadequate response,
which leads to therapy with higher doses of exogenous
EPO. In several studies, such as the Correction of Hemoglo-
bin and Outcomes in Renal Insufficiency (CHOIR) study, the
use of high-dose EPO in EPO-resistant patients was associ-
ated with increased morbidity and mortality.27 Subsequently
it was hypothesized by several authors that a disturbed bone
marrow response to erythropoietin could explain the associ-
ation between morphologic changes in the red blood cell
(RDW) and cardiovascular risk.2,4,12 However, in the current
study, none of the markers of EPO resistance, estimating
both the response to endogenous EPO as well as the response
to exogenous EPO, was associated with RDW. Furthermore,
in our EPO-naive patient group, treatment with exogenous
EPO induced an increase in RDW. This contradicts an asso-
ciation between resistance to EPO and RDW.
We did find a significant correlation between RDW and
markers of erythropoietic activity at baseline (IRF and
sTfR). It is important to note that increased erythropoietic
activity does not necessarily result in increased hemoglobin
levels because the level of hemoglobin is determined by the
red cell production and maturation rate and by the rate of
red cell destruction. IRF is defined as the ratio of young,
immature reticulocytes to the total number of reticulocytes.
IRF is used to assess the degree of erythropoietic activity
(eg, after chemotherapy).18 Circulating reticulocytes shed
the soluble transferrin receptor during their maturation
sequence. This sTfR level correlates more strongly with
corpuscular indices than with iron parameters and is used
as a biomarker of increased erythropoietic activity.29
F€orhecz et al also reported a positive correlation between
sTfR and RDW in a nonanemic cohort of patients with sys-
tolic heart failure.2 This concept is further strengthened by
our results, in which RDW is positively related to erythro-
poietic activity, as measured by both IRF and sTfR, in ane-
mic patients with heart and kidney failure.
RDW is most commonly used in the differential diagnosis
of iron deficiency anemia, in which MCV is decreased and
RDW is increased. Decreased functional iron availability
plays a role in anemia of CHF and CKD. We demonstrate
a negative correlation between baseline TSAT, RET-He,
sTfR, and RDW in our iron-supplemented patients. RET-
He is considered to be a very sensitive indicator reflecting
iron availability for erythropoiesis30 and is an indicator for
iron-restricted erythropoiesis in patients receiving EPO.24
Compared with the use of ferritin or TSAT, it compared bet-
ter in sensitivity and specificity.17 Therefore, although 41%
of our orally iron-supplemented patients had a ferritin
Fig. 1. The correlation between log-transformed baseline red cell distribution width (RDW) values and baseline levels of (A) reticulocyte
hemoglobin content, (B) log-transformed interleukin-6, and (C) log-transformed immature reticulocyte fraction in 54 cardiorenal patients.
RDW and EPO Resistance  Emans et al 631level! 100 ng/mL, indicating possible lower iron stores, the
lack of decrease in RET-He after EPO therapy suggests that
there was no overtly iron-restricted erythropoiesis. Because
we found no association between ferritin levels and RDW,
our data suggest that decreased functional iron availability
but not iron stores play a role in higher RDW values. Our re-
sults correspond with recently published results,2,4 describ-
ing a positive correlation between RDW and TSAT and/or
sTfR, in symptomatic heart failure patients. In addition to
these studies, we determined RET-He, a more sensitive
marker of functional iron availability, which further substan-
tiated the contention that increased RDW values are associ-
ated with decreased functional iron availability.
As mentioned earlier, in our study RDW was associated
with markers of both erythropoietic activity and functional
iron availability. Furthermore, a strong correlation was
observed between RDW and IL-6. It has been hypothesized
that the correlation between RDWand functional iron avail-
ability is mediated by hepcidin.4 Hepcidin is upregulated by
a number of stimuli (eg, anemia and inflammation [IL-6]).
Hepcidin thus integrates input from erythropoietic and
inflammatory pathways.31 In patients with CKD,32 it has
been shown that hepcidin levels are higher compared toFig. 2. The correlation between log-transformed baseline red cell distribu
increase in soluble transferrin receptor, and (C) the increase in immature
35 cardiorenal patients.healthy controls, but in patients with CHF and anemia
this was not confirmed.26,33 In our patients with the combi-
nation of heart and kidney failure and anemia hepcidin-25
levels, were higher. Thus, hepcidin seems an obvious ‘‘can-
didate-linking factor’’ between inflammation and decreased
functional iron availability, leading to higher RDW levels.
However, our data show no clear correlation between
hepcidin-25 and RDW. It should be noted that, because
this is a small study and the P value (P 5 .07) approached
significance, a weak association between RDW and hepci-
din cannot be ruled out. Also, there was no correlation
between hepcidin-25 and inflammation in our patient
group. This finding was confirmed in another study and is
in keeping with our earlier finding that in our group of sta-
bile cardiorenal patients, with relatively low levels of
inflammatory biomarkers, increased hepcidin levels were
associated with markers of iron load (ferritin) rather than
with markers of inflammation.25,26 Thus, in our study,
RDW was associated with IL-6 but not with other markers
of inflammation. Although data exist that IL-6 can influ-
ence iron absorption during the hypoxic exposure, via
a mechanism independent of hepcidin,34 at this point it is
unclear how IL-6 is related to an increase in RDW.tion width (RDW) values and (A) the reticulocyte increase, (B) the
reticulocyte fraction, after 2 weeks of erythropoietin treatment in
632 Journal of Cardiac Failure Vol. 17 No. 8 August 2011RDW is elevated in conditions of increased erythropoie-
sis/ineffective erythropoiesis and in conditions of increased
red cell destruction. RDW increases when the relative num-
ber of larger and/or smaller red blood cells increases.
Because RDW is not correlated toMCV in our patient group,
it can be hypothesized that the changes in RDW are caused
by both an increase in the relative number of large red cells
as well as an increase of the relative number of small red cells
in the peripheral blood. Indeed, MCV positively correlated
with both RET-He (r 5 0.387, P 5 .004) as well as with
IRF (r 5 0.245, P 5 .08). The absence of a correlation
between RDW and MCV in our anemic patients thus may
be due to a balanced net effect of increased erythropoietic
activity leading to a higher MCV and decreased iron avail-
ability, leading to a lower MCV.
Finally, limitations of the study as result of sample size
and selection bias need to be acknowledged. The cohort
size of the 2-center EPOCARES study is rather small.
Studying simple associations and constructing a multivari-
ate model using a relatively small sample size is of limited
value, although most of the associations we report are
robust despite the small sample size. However, we cannot
fully exclude the possibility that the lack of association
between some parameters (eg, hepcidin, RDW) is due to
lack of power. This patient group comprised anemic
patients with both CHF and CKD; therefore, these results
should be carefully interpreted and cannot be generalized
to all patients with CHF, especially those patients without
renal dysfunction. Also, the EPOCARES patients were
receiving multiple drugs, including oral iron supplementa-
tion, throughout the study, and were in a relatively low in-
flammatory state. This might not fully represent daily
clinical practice on which data of RDW as biomarker for
outcome are based.
In conclusion, EPO resistance was not associated with
RDW in these iron-supplemented anemic patients with
CKD and CHF. However, RDW was associated with eryth-
ropoietic activity, decreased functional iron availability and
IL-6. We found no significant correlation between hepcidin
and RDW. In our view, as also pointed out by Allen et al,
the association of RDW with outcome may imply that the
erythrocyte may be viewed as a ‘‘barometer’’ of overall car-
diovascular health.4 Therefore mechanisms that cause
changes in relative distribution of red cell size such as
increased erythropoietic activity, increased red cell destruc-
tion, and reduced red cell half life should be investigated.Acknowledgments
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